FDA grants Breakthrough Therapy Designation to Raludotatug Deruxtecan for CDH6+ platinum-resistant ovarian and related cancers previously treated with bevacizumab Raludotatug deruxtecan (R-DXd) has been granted Breakthrough Therapy Designation (BTD) by the U.S. Food and Drug Administration (FDA) for the treatment…
EU approves first oral GLP-1 RA to cut cardiovascular risk Novo Nordisk today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has approved an update to the Rybelsus® (oral semaglutide) label to reflect the cardiovascular…
People taking Novo Nordisk’s Wegovy® experienced reduced food noise and boosted mental well-being Novo Nordisk today announced results from the US-based INFORM survey of people taking semaglutide for weight management (Wegovy®), at the European Association for the Study of Diabetes…
Cholera Deaths Rise for Second Year Despite Available Prevention and Treatment The World Health Organization (WHO) has published its global cholera statistics for 2024, showing an increase in both the number of people who fell sick and died from the disease.…
Ionis expands Surf Away+ event, marking 10 years of creating unique adaptive experiences for people with neurological diseases Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today celebrated 10 years of Surf Away+, an inclusive adaptive event for rare neurological disease communities. Originally created…
Modeyso™ (Dordaviprone) Gains Inclusion in NCCN Clinical Practice Guidelines, Marking a Milestone in the Treatment of H3 K27M-Mutant Diffuse Glioma Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced a pivotal development for its oncology portfolio with the inclusion of Modeyso™ (dordaviprone) in…
Novartis to Acquire Tourmaline Bio, Advancing Cardiovascular Pipeline with Pacibekitug for ASCVD Novartis today revealed a major step forward in its cardiovascular disease (CVD) strategy with the announcement that it has entered into an agreement to acquire Tourmaline Bio, Inc.…
Cascade Bio Secures $6 Million to Advance Biocatalyst Innovation and Transform Biomanufacturing In a world grappling with climate change, supply chain disruptions, and the growing demand for sustainable manufacturing, biotechnology companies are racing to create alternatives to petrochemical-based production. Cascade…
RION Launches INTENT Biologics to Advance Late-Stage Clinical Exosome Therapies in Inflammation & Immunology; Appoints Industry Leader Suneet Varma as CEO RION, a clinical-stage regenerative medicine company recognized globally for its pioneering work in exosome-based therapeutics, has announced the formation…
JCR Pharmaceuticals Showcases Landmark Five-Year Clinical Data on Pabinafusp Alfa at ICIEM 2025, Reinforcing Transformative Potential for Patients with Hunter Syndrome and Expanding Pipeline of Brain-Penetrant Enzyme Replacement Therapies In early September 2025, the city of Kyoto, Japan, became the…
Tolerance Bio and ZipCode Bio Forge Strategic R&D Collaboration to Advance Targeted Thymus Therapeutics In a landmark move that underscores the growing intersection of immunology and RNA-based medicine, Tolerance Bio, a young biopharmaceutical company dedicated to extending healthspan by preserving…
FDA Expands Approval of Takeda’s VONVENDI®, First Recombinant von Willebrand Factor Therapy, to Include Routine Prophylaxis for Adults and Children with von Willebrand Disease Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK), a global biopharmaceutical leader with a longstanding commitment to advancing therapies…
